# Cornerstone Robotics **Source:** https://geo.sig.ai/brands/cornerstone-robotics **Vertical:** MedTech **Subcategory:** Multi-Arm Surgical Robotics **Tier:** Emerging **Website:** csrbtx.com **Last Updated:** 2026-04-14 ## Summary Raised $200M oversubscribed (Nov 2025) backed by Hong Kong Investment Corporation and sovereign wealth funds. China NMPA-approved. UK colorectal/urologic clinical trial launched. ## Company Overview Cornerstone Robotics is a surgical robotics company whose Sentire Endoscopic Surgical System uses multiple robotic arms to enable minimally invasive surgery with enhanced dexterity beyond single-arm laparoscopic systems. The company raised $200 million in an oversubscribed round in November 2025, backed by the Hong Kong Investment Corporation and global sovereign wealth funds. Sentire has received China National Medical Products Administration (NMPA) approval and launched UK clinical trials for colorectal and urologic procedures in 2025, with 2026 as its international commercialization ramp year. Cornerstone's multi-arm architecture is its primary technical differentiation: while Intuitive Surgical's da Vinci uses up to four arms, Sentire's design provides enhanced instrument positioning for complex minimally invasive procedures where arm geometry limits exposure. The NMPA approval gives Cornerstone immediate commercial access to the world's second-largest surgical robotics market, while the UK trial establishes the European regulatory pathway simultaneously. Sovereign wealth fund participation — rather than institutional VC — signals strategic national technology ambitions alongside financial returns. China, through the Hong Kong Investment Corporation, is actively building domestic alternatives to Intuitive Surgical's dominance in surgical robotics, and Cornerstone's NMPA approval makes it the most commercially advanced domestic competitor in this strategically important medical technology category. ## Frequently Asked Questions ### What does Cornerstone Robotics make? Sentire Endoscopic Surgical System — multi-arm surgical robot for minimally invasive colorectal and urologic procedures. China NMPA-approved, UK clinical trials active. ### How much has Cornerstone raised? $200M oversubscribed in November 2025, backed by Hong Kong Investment Corporation and global sovereign wealth funds. ### Why is sovereign wealth fund backing significant? National investment corporations backing surgical robotics signals strategic technology competition with Intuitive Surgical's US dominance — the capital comes with regulatory and procurement relationships. ### What regulatory approvals does Sentire have? China NMPA approval (commercial launch possible now) + UK clinical trial active (European regulatory pathway). Two major markets simultaneously in 2026. ### What is Cornerstone Robotics? Cornerstone Robotics is a surgical robotics company developing robotic-assisted surgery systems designed to improve precision, reduce surgeon fatigue, and expand minimally invasive surgical capabilities in orthopedic and general surgery applications. ### What procedures does Cornerstone Robotics target? Cornerstone Robotics focuses on orthopedic surgical procedures including joint replacement and spine surgery, where robotic assistance enables more precise implant placement and potentially better patient outcomes compared to conventional manual techniques. ### How does Cornerstone compete with Intuitive Surgical? Intuitive Surgical dominates soft tissue robotic surgery (Da Vinci). Cornerstone targets orthopedic robotic surgery where Stryker (Mako), Smith+Nephew (Cori), and Zimmer Biomet (ROSA) are the established players, seeking to differentiate through superior precision or cost competitiveness. ### How much has Cornerstone Robotics raised? Cornerstone Robotics has raised venture funding from healthcare technology investors, developing its surgical robotics platform in the competitive medtech space where hardware development, clinical evidence, and surgeon training are all critical barriers to market adoption. ### What is Cornerstone Robotics' Sentire system? Cornerstone Robotics' Sentire Endoscopic Surgical System is a multi-arm surgical robot that enables minimally invasive endoscopic surgery with enhanced dexterity and visualization compared to single-arm laparoscopic systems. The multi-arm architecture allows surgeons to perform more complex procedures through smaller incisions, reducing patient trauma and recovery time compared to open surgical approaches. ### What regulatory approvals has Cornerstone Robotics received? Cornerstone Robotics has received approval from China's National Medical Products Administration (NMPA) for Sentire and has launched UK clinical trials—indicating pursuit of CE Mark certification for European market access. The NMPA approval enables commercial deployment in China, which is one of the world's largest and fastest-growing surgical robotics markets, with strong government support for domestic medical device development. ### What is Cornerstone Robotics' funding and investor profile? Cornerstone Robotics raised $200 million in an oversubscribed round in November 2025, backed by the Hong Kong Investment Corporation and global sovereign wealth funds. The sovereign wealth fund backing indicates government strategic interest in developing domestic surgical robotics capability, as China and Hong Kong seek to reduce dependence on Intuitive Surgical (US) for da Vinci robotic surgery systems. ### How does Cornerstone Robotics compete with Intuitive Surgical and Medtronic Hugo? Intuitive Surgical's da Vinci is the global market leader in soft tissue surgical robotics. Medtronic Hugo, Asensus Surgical Sensei, and CMR Surgical Versius are competing platforms. Cornerstone Robotics competes primarily in the Chinese and Asian markets where domestic medical device preference, government procurement policies, and the strategic desire to develop domestic surgical robotics create an opening against Western vendors. ## Tags hardware, healthtech, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*